Preclinical data strongly indicate that identifying combinations, either with targeted agents or with chemotherapy, might be the key to unleashing the full potential of mTOR inhibitors in T-ALL patients, as we have highlighted in this review. Here, MTOR is linked to acute lymphoblastic leukemia.